•
•
•
•
•
•
•
•
Sources
Mentions
Mentions of this stock across all news source scraped in the past 30 days
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
investing.com
40%
Fintel
20%
seekingalpha.com
20%
Others
20%
Country
US
Industry
Health Care
Market Cap
Small Cap
Num. Employees
280
IPO Date
Sep 18, 2019
Country
US
Industry
Health Care
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 280 full-time employees. The company went IPO on 2019-09-18. The firm has created an IgM antibody technology platform for developing T cell engagers, receptor cross-linking agonists, targeted cytokines and target neutralizers. Its product candidates in clinical testing include IGM-2323 and IGM-8444. IGM-2323 is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in a Phase II clinical trial for the treatment of relapsed/refractory B cell non-Hodgkins lymphoma (NHL) patients. IGM-8444 is an IgM antibody targeting Death Receptor 5 (DR5) proteins for the treatment of patients with solid and hematologic malignancies, is in a Phase I clinical trial for the treatment of solid cancers. Its oncology pipeline also includes IGM-7354, IGM-2644 and IGM-2537.
On Tuesday, Truist Securities adjusted its stance on IGM Biosciences (NASDAQ:IGMS) shares, moving the rating from Buy to Hold and halving the price target to $12 from the previous $24.
Recent Mentions
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
News Sentiment
Sentiment
Composite sentiment (positive vs. negative language) expressed across news sources mentioning this stock
Today
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Low Data
Related Stocks
Related Stocks
Stocks being mentioned with IGMS